Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Lowered by Zacks Research

Day One Biopharmaceuticals (NASDAQ:DAWN) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

DAWN has been the topic of a number of other research reports. Wedbush increased their price objective on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday. TD Cowen assumed coverage on Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price target on the stock. HC Wainwright decreased their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday. Needham & Company LLC lowered their target price on Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Piper Sandler lifted their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.14.

Day One Biopharmaceuticals Stock Down 2.6%

Shares of NASDAQ:DAWN opened at $10.65 on Wednesday. Day One Biopharmaceuticals has a 52-week low of $5.64 and a 52-week high of $13.20. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -10.34 and a beta of -1.26. The business has a 50-day moving average price of $10.69 and a 200-day moving average price of $8.77.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The business had revenue of $53.72 million during the quarter, compared to analyst estimates of $49.81 million. As a group, equities analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Activity

In related news, insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the transaction, the insider owned 4,397 shares in the company, valued at $51,005.20. The trade was a 38.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeremy Bender sold 15,459 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $179,324.40. Following the transaction, the chief executive officer owned 204,603 shares in the company, valued at $2,373,394.80. This represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of large investors have recently added to or reduced their stakes in DAWN. Vanguard Group Inc. lifted its holdings in Day One Biopharmaceuticals by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company’s stock valued at $58,552,000 after purchasing an additional 101,047 shares in the last quarter. Vestal Point Capital LP lifted its stake in Day One Biopharmaceuticals by 94.4% in the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after buying an additional 2,525,000 shares in the last quarter. Deerfield Management Company L.P. raised its holdings in shares of Day One Biopharmaceuticals by 26.4% during the third quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock valued at $33,173,000 after acquiring an additional 982,282 shares during the last quarter. State Street Corp increased its position in shares of Day One Biopharmaceuticals by 32.4% during the fourth quarter. State Street Corp now owns 4,289,566 shares of the company’s stock worth $39,979,000 after purchasing an additional 1,049,122 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Day One Biopharmaceuticals by 2.0% during the second quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock worth $26,635,000 after purchasing an additional 79,255 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Wedbush raised its price target to $30 and kept an “outperform” rating, signaling strong upside potential from current levels and offering a bullish institutional endorsement. Wedbush PT Raise
• Positive Sentiment: Revenue beat — Q4 revenue came in above consensus (company reported ~$53.7M vs est. ~$49.8M), described as record revenue growth, which supports top‑line momentum and future commercial prospects. Earnings Highlights
• Neutral Sentiment: Analyst roundup pieces summarizing multiple firms’ views are circulating, providing varied takes that can sustain volatility as investors parse differing price targets and ratings. Analyst Roundup
• Neutral Sentiment: Short-interest report shows 0 shares noted for the period (data appears anomalous), so current short-interest metrics provide no clear signal and should be treated cautiously.
• Neutral Sentiment: Earnings materials and full transcripts are available for deeper review (presentation and call transcripts), useful for investors who want management commentary on guidance, commercial rollout and cost trajectory. Earnings Presentation
• Negative Sentiment: EPS missed expectations — Q4 GAAP loss was $0.21 per share vs. the consensus loss of $0.17, highlighting ongoing profitability pressure and contributing to near-term downside risk. EPS Miss Coverage
• Negative Sentiment: Some analysts trimmed price targets (Needham cut to $17; HC Wainwright lowered to $22) even while keeping “buy” ratings — these reductions reduce consensus upside and can weigh on sentiment despite revenue strength. Analyst PT Changes

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.